Goldman Sachs Group Inc. Has $5.05 Million Stock Holdings in AxoGen, Inc. $AXGN

Key Points

• Goldman Sachs Group Inc. reduced its stake in AxoGen, Inc. by 13.3%, now owning 272,814 shares worth approximately $5 million after selling 41,877 shares in the first quarter.
• Institutional ownership of AxoGen is high, with over 80% of the company's stock held by various institutional investors, including significant increases from Invesco Ltd. and Driehaus Capital Management.
• Wall Street analysts have upgraded AxoGen's stock rating from "hold" to "buy," with a consensus price target of $26.00.

Goldman Sachs Group Inc. decreased its position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 13.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 272,814 shares of the medical equipment provider's stock after selling 41,877 shares during the quarter. Goldman Sachs Group Inc. owned about 0.60% of AxoGen worth $5,047,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Fifth Third Bancorp acquired a new stake in AxoGen in the 1st quarter valued at about $92,000. Acadian Asset Management LLC increased its holdings in AxoGen by 41.0% in the first quarter. Acadian Asset Management LLC now owns 226,812 shares of the medical equipment provider's stock worth $4,194,000 after buying an additional 65,929 shares during the last quarter. Northern Trust Corp increased its holdings in AxoGen by 1.5% in the fourth quarter. Northern Trust Corp now owns 383,127 shares of the medical equipment provider's stock worth $6,314,000 after buying an additional 5,838 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in AxoGen by 148.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 203,901 shares of the medical equipment provider's stock worth $3,772,000 after purchasing an additional 121,901 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of AxoGen by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider's stock valued at $398,000 after purchasing an additional 926 shares during the period. Institutional investors and hedge funds own 80.29% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised AxoGen from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.00.

AxoGen Trading Down 0.3%

AXGN stock traded down $0.06 during midday trading on Friday, reaching $17.20. The stock had a trading volume of 997,621 shares, compared to its average volume of 1,084,691. The firm has a market cap of $791.37 million, a price-to-earnings ratio of -171.98 and a beta of 1.03. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $21.00. The business has a fifty day simple moving average of $14.63 and a two-hundred day simple moving average of $14.18. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.